92
May 28 – 30, 2015, Montréal, Québec Contrast Nephropathy Swapnil Hiremath, MD, MPH @hswapnil Nephrologist The Ottawa Hospital University of Ottawa Ottawa Hospital Research Institute

Contrast-induced Acute Kidney Injury

Embed Size (px)

Citation preview

May 28 – 30, 2015, Montréal, Québec

Contrast Nephropathy

Swapnil Hiremath, MD, MPH@hswapnilNephrologist

The Ottawa HospitalUniversity of Ottawa

Ottawa Hospital Research Institute

May 28 – 30, 2015, Montréal, Québec

Disclosure Statement: With a Conflict of Interest

Financial:

• Study funding: GE Healthcare is funding an economic analysis to study the impact of osmolality of contrast medium and acute kidney injury

• I own no stock or securities nor do I serve or have served as a consultant for any drug or device manufacturer

Others:

• I am the PI of an ongoing trial examining oral hydration (vs IV) to prevent contrast nephropathy

• I am a co-author of the Canadian Association of Radiology (CAR) guidelines

CAMRT joint Congress May 2015

Objectives

At the end of this talk, the listener will

• Identify patients who are at high risk of contrast nephropathy

• Know what to order to minimize risk of contrast nephropathy

CAMRT joint Congress May 2015

What is Contrast Nephropathy*?

*Now known as Contrast-induced

Acute Kidney Injury

Following Contrast exposure:

Arterial (cardiac cath, arteriograms)

Venous (CT Scans)

CAMRT joint Congress May 2015

What is Contrast Nephropathy*?

• Acute Kidney Injury, defined as:

• Rise in creatinine of 25%

• Rise in creatinine of 44 micromol/L

• A much smaller proportion: Dialysis or Death

*Now known as Contrast-induced

Acute Kidney Injury

Following Contrast exposure:

Arterial (cardiac cath, arteriograms)

Venous (CT Scans)

CAMRT joint Congress May 2015

Case

CAMRT joint Congress May 2015

Case• 59 year old gentleman, DM2

• Worsening angina

• Cr 170 at baseline (eGFR 38)

CAMRT joint Congress May 2015

Case• 59 year old gentleman, DM2

• Worsening angina

• Cr 170 at baseline (eGFR 38)

CAMRT joint Congress May 2015

Case• 59 year old gentleman, DM2

• Worsening angina

• Cr 170 at baseline (eGFR 38)

CAMRT joint Congress May 2015

Pathophysiology

from: cJASN Jan 2008

CAMRT joint Congress May 2015

Pathophysiology

from: cJASN Jan 2008

CAMRT joint Congress May 2015

Pathophysiology

• Courtesy Prof Persson, Berlin

CAMRT joint Congress May 2015

Which patients are at risk?

CAMRT joint Congress May 2015

Which patients are at risk?

• Arterial contrast (Cardiac Catheterization, Angiograms) >> Venous Contrast (Contrast enhanced CT scans)

CAMRT joint Congress May 2015

Which patients are at risk?

• Arterial contrast (Cardiac Catheterization, Angiograms) >> Venous Contrast (Contrast enhanced CT scans)

• Diabetes, Dehydration

CAMRT joint Congress May 2015

Which patients are at risk?

• Arterial contrast (Cardiac Catheterization, Angiograms) >> Venous Contrast (Contrast enhanced CT scans)

• Diabetes, Dehydration

• Severe Chronic Kidney Disease (eGFR < 30, stage 4 and 5 CKD)

CAMRT joint Congress May 2015

How should we prevent Contrast - AKI?Literature Roundup

>8000 publications

14 + 57 + 22 + 18=113 RCTs

(4 interventions)

3412 with RCT filter

42 Meta-analyses

CAMRT joint Congress May 2015

How should we prevent Contrast - AKI?Literature Roundup

>8000 publications

14 + 57 + 22 + 18=113 RCTs

(4 interventions)

3412 with RCT filter

42 Meta-analyses

+ 82 studies currently recruiting

(per Clinicaltrials.gov)

CAMRT joint Congress May 2015

N-Acetyl Cysteine (mucomyst)

CAMRT joint Congress May 2015

N-Acetyl Cysteine: Mixed Evidence?

Gonzales et al, BMC Medicine, 2007

CAMRT joint Congress May 2015

N-Acetyl Cysteine: Mixed Evidence?

Gonzales et al, BMC Medicine, 2007

CAMRT joint Congress May 2015

N-Acetyl Cysteine: Mixed Evidence?

Gonzales et al, BMC Medicine, 2007

CAMRT joint Congress May 2015

N-Acetyl Cysteine: Definitive Evidence

CAMRT joint Congress May 2015

N-Acetyl Cysteine: Definitive Evidence

CAMRT joint Congress May 2015

N-Acetyl Cysteine: Definitive Evidence

ACT study, Berwanger et al, Circulation, 2011

N = 2272

CAMRT joint Congress May 2015

N-Acetyl Cysteine: Definitive Evidence

ACT study, Berwanger et al, Circulation, 2011

N = 2272

CAMRT joint Congress May 2015

Volume Expansion: Bicarb

CAMRT joint Congress May 2015

Volume Expansion: Bicarb

CAMRT joint Congress May 2015

Volume Expansion: Bicarb

Merten et al, JAMA 2004

N = 119

CAMRT joint Congress May 2015

Volume Expansion: Bicarb or Saline?

CAMRT joint Congress May 2015

Volume Expansion: Bicarb or Saline?

CAMRT joint Congress May 2015

Volume Expansion: Bicarb or Saline?

CAMRT joint Congress May 2015

Volume Expansion: Bicarb or Saline?

CAMRT joint Congress May 2015

Oral hydration?

Source: Hiremath et al, PLoS One, 2013Small number of studiesOngoing trial at Ottawa

CAMRT joint Congress May 2015

Safer Contrast Media

CAMRT joint Congress May 2015

Safer Contrast MediaIonicity Relative

OsmolalityOsmolality (mOsm/kg H20)

Examples

Ionic monomers High osmolality 1500 – 1900 Diatrizoate, Iothalamate, Metrizoate, Iodamide, Ioxithalamate

Ionic dimers Low osmolality 600 IoxaglateNonionic monomers Low osmolality 500 – 700 Iopamidol,

Iohexol,Iomeprol,Iopentol,Iopromide,Ioversol,Ioxitol,Metrizamide

Nonionic dimers Iso-osmolal 290-320 Iodixanol,Iotrolan

CAMRT joint Congress May 2015

Safer Contrast MediaIonicity Relative

OsmolalityOsmolality (mOsm/kg H20)

Examples

Ionic monomers High osmolality 1500 – 1900 Diatrizoate, Iothalamate, Metrizoate, Iodamide, Ioxithalamate

Ionic dimers Low osmolality 600 IoxaglateNonionic monomers Low osmolality 500 – 700 Iopamidol,

Iohexol,Iomeprol,Iopentol,Iopromide,Ioversol,Ioxitol,Metrizamide

Nonionic dimers Iso-osmolal 290-320 Iodixanol,Iotrolan

CAMRT joint Congress May 2015

Safer Contrast MediaIonicity Relative

OsmolalityOsmolality (mOsm/kg H20)

Examples

Ionic monomers High osmolality 1500 – 1900 Diatrizoate, Iothalamate, Metrizoate, Iodamide, Ioxithalamate

Ionic dimers Low osmolality 600 IoxaglateNonionic monomers Low osmolality 500 – 700 Iopamidol,

Iohexol,Iomeprol,Iopentol,Iopromide,Ioversol,Ioxitol,Metrizamide

Nonionic dimers Iso-osmolal 290-320 Iodixanol,Iotrolan

CAMRT joint Congress May 2015

Safer Contrast MediaIonicity Relative

OsmolalityOsmolality (mOsm/kg H20)

Examples

Ionic monomers High osmolality 1500 – 1900 Diatrizoate, Iothalamate, Metrizoate, Iodamide, Ioxithalamate

Ionic dimers Low osmolality 600 IoxaglateNonionic monomers Low osmolality 500 – 700 Iopamidol,

Iohexol,Iomeprol,Iopentol,Iopromide,Ioversol,Ioxitol,Metrizamide

Nonionic dimers Iso-osmolal 290-320 Iodixanol,Iotrolan

CAMRT joint Congress May 2015

Safer Contrast MediaIonicity Relative

OsmolalityOsmolality (mOsm/kg H20)

Examples

Ionic monomers High osmolality 1500 – 1900 Diatrizoate, Iothalamate, Metrizoate, Iodamide, Ioxithalamate

Ionic dimers Low osmolality 600 IoxaglateNonionic monomers Low osmolality 500 – 700 Iopamidol,

Iohexol,Iomeprol,Iopentol,Iopromide,Ioversol,Ioxitol,Metrizamide

Nonionic dimers Iso-osmolal 290-320 Iodixanol,Iotrolan

CAMRT joint Congress May 2015

Safer Contrast Media

• Low Osmolar >>safer then High Osmolar (Barrett et al, Radiology 1993)

Ionicity Relative Osmolality

Osmolality (mOsm/kg H20)

Examples

Ionic monomers High osmolality 1500 – 1900 Diatrizoate, Iothalamate, Metrizoate, Iodamide, Ioxithalamate

Ionic dimers Low osmolality 600 IoxaglateNonionic monomers Low osmolality 500 – 700 Iopamidol,

Iohexol,Iomeprol,Iopentol,Iopromide,Ioversol,Ioxitol,Metrizamide

Nonionic dimers Iso-osmolal 290-320 Iodixanol,Iotrolan

CAMRT joint Congress May 2015

Safer Contrast Media

• Low Osmolar >>safer then High Osmolar (Barrett et al, Radiology 1993)

• Iso-osmolar versus Low osmolar?

Ionicity Relative Osmolality

Osmolality (mOsm/kg H20)

Examples

Ionic monomers High osmolality 1500 – 1900 Diatrizoate, Iothalamate, Metrizoate, Iodamide, Ioxithalamate

Ionic dimers Low osmolality 600 IoxaglateNonionic monomers Low osmolality 500 – 700 Iopamidol,

Iohexol,Iomeprol,Iopentol,Iopromide,Ioversol,Ioxitol,Metrizamide

Nonionic dimers Iso-osmolal 290-320 Iodixanol,Iotrolan

CAMRT joint Congress May 2015

Use Safer Contrast media

CAMRT joint Congress May 2015

Use Safer Contrast media

CAMRT joint Congress May 2015

Use Safer Contrast media

Aspelin et al, New Engl J Med, 2003

N = 129

CAMRT joint Congress May 2015

Is Iodixanol truly superior?

CAMRT joint Congress May 2015

Is Iodixanol truly superior?

CAMRT joint Congress May 2015

Is Iodixanol truly superior?

CARE study, Solomon et al, Circulation, 2007

N = 414

CAMRT joint Congress May 2015

Is Iodixanol truly superior?

CAMRT joint Congress May 2015

Is Iodixanol truly superior?

CAMRT joint Congress May 2015

Meta-Analysis: LOCM vs IsoCM

CAMRT joint Congress May 2015

Meta-Analysis: LOCM vs IsoCM

CAMRT joint Congress May 2015

Meta-Analysis: LOCM vs IsoCM

CAMRT joint Congress May 2015

Meta-Analysis: LOCM vs IsoCM

CAMRT joint Congress May 2015

Iodixanol vs Iohexol

CAMRT joint Congress May 2015

Iodixanol vsOther LOCMs

CAMRT joint Congress May 2015

What about Dialysis to remove contrast?

CAMRT joint Congress May 2015

What about Dialysis to remove contrast?

Cruz et al, AJKD, 2007

CAMRT joint Congress May 2015

What about Dialysis to remove contrast?

Cruz et al, AJKD, 2007

CAMRT joint Congress May 2015

What about Dialysis to remove contrast?

Marenzi et al, New Engl J Med, 2003

N = 114

Cruz et al, AJKD, 2007

CAMRT joint Congress May 2015

What about Dialysis to remove contrast?

CAMRT joint Congress May 2015

What about Dialysis to remove contrast?

CAMRT joint Congress May 2015

What about Dialysis to remove contrast?

Reinecke et al, Clin Res Cardiol, 2007

CAMRT joint Congress May 2015

Comparison of Effect Sizes

CAMRT joint Congress May 2015

Comparison of Effect Sizes

Intervention First Study Best Study

N-Acetyl Cysteine 0.1 1.01

Bicarb-based Hydration 0.125 0.94

Dialysis after Contrast 0.1 0.90

Iso-osmolar vs low-osmolar Contrast

0.09 1.13

CAMRT joint Congress May 2015

Comparison of Effect Sizes

Intervention First Study Best Study

N-Acetyl Cysteine 0.1 1.01

Bicarb-based Hydration 0.125 0.94

Dialysis after Contrast 0.1 0.90

Iso-osmolar vs low-osmolar Contrast

0.09 1.13

CAMRT joint Congress May 2015

Comparison of Effect Sizes

Intervention First Study Best Study

N-Acetyl Cysteine 0.1 1.01

Bicarb-based Hydration 0.125 0.94

Dialysis after Contrast 0.1 0.90

Iso-osmolar vs low-osmolar Contrast

0.09 1.13

CAMRT joint Congress May 2015

Comparison of Effect SizesIntervention

First Study

Best Study

N-Acetyl Cysteine 0.1

NEJM1.01

CirculationN-Acetyl Cysteine 0.1

N = 831.01

N =2400

Bicarb-based Hydration 0.125

JAMA0.94

JAMABicarb-based Hydration 0.125

N =1190.94

N = 353

Dialysis after Contrast 0.1

NEJM0.90

CRCDialysis after Contrast 0.1

N = 1140.90

N = 424

Iso-osmolar Contrast 0.09

NEJM1.13

JACCIso-osmolar Contrast 0.09

N = 1291.13

N = 418

CAMRT joint Congress May 2015

Contrast media

Does Venous Contrast cause Acute Kidney

Injury?

CAMRT joint Congress May 2015

Contrast media Acute Kidney Injury

Does Venous Contrast cause Acute Kidney

Injury?

CAMRT joint Congress May 2015

Contrast media Acute Kidney Injury

Does Venous Contrast cause Acute Kidney

Injury?

CAMRT joint Congress May 2015

Contrast media Acute Kidney Injury

SepsisCardiogenic Shock

Does Venous Contrast cause Acute Kidney

Injury?

CAMRT joint Congress May 2015

Contrast media Acute Kidney Injury

SepsisCardiogenic Shock

Does Venous Contrast cause Acute Kidney

Injury?

CAMRT joint Congress May 2015

Contrast-induced

Contrast media Acute Kidney Injury

SepsisCardiogenic Shock

Does Venous Contrast cause Acute Kidney

Injury?

CAMRT joint Congress May 2015

Contrast-associated

Contrast media Acute Kidney Injury

SepsisCardiogenic Shock

Does Venous Contrast cause Acute Kidney

Injury?

CAMRT joint Congress May 2015

Does Venous ContrastCause AKI?

Source: Radiology, 2014

CAMRT joint Congress May 2015

Does Venous ContrastCause AKI?

Source: Radiology, 2014

CAMRT joint Congress May 2015

Others

• If hydration helps, so will stopping diuretics

• Potentially nephrotoxic medications: NSAIDs, others

• RAS Blockade? (ACE inhibitors, Angiotensin receptor blockers, renin inhibitors, spironolactone)

• Statins

CAMRT joint Congress May 2015

Metformin and Contrast?

CAMRT joint Congress May 2015

Metformin and Contrast?• Metformin is NOT nephrotoxic;

phenformin, its predecessor was banned for causing lactic acidosis. Case reports exist with metformin as well

CAMRT joint Congress May 2015

Metformin and Contrast?• Metformin is NOT nephrotoxic;

phenformin, its predecessor was banned for causing lactic acidosis. Case reports exist with metformin as well

• So, if a patient is on metformin AND

CAMRT joint Congress May 2015

Metformin and Contrast?• Metformin is NOT nephrotoxic;

phenformin, its predecessor was banned for causing lactic acidosis. Case reports exist with metformin as well

• So, if a patient is on metformin AND

• Is given contrast AND

CAMRT joint Congress May 2015

Metformin and Contrast?• Metformin is NOT nephrotoxic;

phenformin, its predecessor was banned for causing lactic acidosis. Case reports exist with metformin as well

• So, if a patient is on metformin AND

• Is given contrast AND

• Develops severe AKI (GFR <20) AND

CAMRT joint Congress May 2015

Metformin and Contrast?• Metformin is NOT nephrotoxic;

phenformin, its predecessor was banned for causing lactic acidosis. Case reports exist with metformin as well

• So, if a patient is on metformin AND

• Is given contrast AND

• Develops severe AKI (GFR <20) AND

• Metformin is not stopped THEN

CAMRT joint Congress May 2015

Metformin and Contrast?• Metformin is NOT nephrotoxic;

phenformin, its predecessor was banned for causing lactic acidosis. Case reports exist with metformin as well

• So, if a patient is on metformin AND

• Is given contrast AND

• Develops severe AKI (GFR <20) AND

• Metformin is not stopped THEN

• There is a possibility of lactic acidosis

CAMRT joint Congress May 2015

Metformin and Contrast?

‘ The legacy of phenformin, anecdotes, scattered case reports, product inserts and medicolegal anxieties are more at the heart of this issue than scientific fact’ - Gerald Pond, Radiology, 2001

CAMRT joint Congress May 2015

Summary

CAMRT joint Congress May 2015

Summary• Contrast procedures have become safer with

time

CAMRT joint Congress May 2015

Summary• Contrast procedures have become safer with

time

• IV (eg CT scans) contrast is considerably less harmful than IA contrast (eg cardiac cath)

CAMRT joint Congress May 2015

Summary• Contrast procedures have become safer with

time

• IV (eg CT scans) contrast is considerably less harmful than IA contrast (eg cardiac cath)

• CKD stage 4 & 5 (GFR < 30) might still be at risk of AKI with CT Scans

CAMRT joint Congress May 2015

Summary• Contrast procedures have become safer with

time

• IV (eg CT scans) contrast is considerably less harmful than IA contrast (eg cardiac cath)

• CKD stage 4 & 5 (GFR < 30) might still be at risk of AKI with CT Scans

• Most prophylactic measures (bicarb, NAC, dialysis) don’t work; except for volume expansion